At Amgen, artificial intelligence (AI) is more than a technological advancement-it's a pivotal force transforming the future of biotechnology. "We're living through a 'hinge moment,' merging tech and biotech to revolutionize drug discovery and development, manufacturing and commercialization," says David Reese, Amgen's first chief technology officer, and former head of Research and Development. "By harnessing AI, Amgen is focused on accelerating the delivery of new therapies, [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.
Disclaimer
Amgen Inc. published this content on
22 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
22 May 2024 15:42:01 UTC.